Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature

Am J Hematol. 2020 Sep;95(9):E218-E222. doi: 10.1002/ajh.25832. Epub 2020 Apr 29.

Authors

Michelle Nadeau Nguyen¹, Afrouz Nayernama¹, S Christopher Jones¹, Bindu Kanapuru², Nicole Gormley², Peter E Waldron¹

Affiliations

¹ Division of Pharmacovigilance, Office of Surveillance and Epidemiology, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
² Division of Hematologic Malignancies, Office of Oncologic Diseases, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

PMID: 32291777
DOI: 10.1002/ajh.25832

No abstract available

Publication types

Letter
Review

MeSH terms

Adverse Drug Reaction Reporting Systems*
Humans
Lymphoma, Mantle-Cell / drug therapy
Lymphoma, Mantle-Cell / epidemiology
Multiple Myeloma / drug therapy
Multiple Myeloma / epidemiology
Proteasome Inhibitors / adverse effects*
Proteasome Inhibitors / therapeutic use
Thrombotic Microangiopathies* / chemically induced
Thrombotic Microangiopathies* / epidemiology
United States / epidemiology
United States Food and Drug Administration*

Substances

Proteasome Inhibitors